The Potential of Long-Acting, Injectable PrEP, and Impediments to its Uptake

J Urban Health. 2023 Feb;100(1):212-214. doi: 10.1007/s11524-022-00711-w. Epub 2023 Jan 11.

Authors

Amitai S Miller¹, Douglas S Krakower^{2

3

4}, Kenneth H Mayer^{2

3

4

5}

Affiliations

¹ Harvard Medical School, Boston, MA, USA. Amiller@hms.harvard.edu.
² Harvard Medical School, Boston, MA, USA.
³ The Fenway Institute, Boston, MA, USA.
⁴ Department of Infectious Disease, Beth Israel Deaconess Medical Center, Boston, MA, USA.
⁵ Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

No abstract available

Keywords: Cabotegravir; HIV; HIV prevention; Injectable pre-exposure prophylaxis; PrEP.

Publication types

Editorial
Research Support, N.I.H., Extramural

MeSH terms

Anti-HIV Agents* / therapeutic use
HIV Infections* / drug therapy
HIV Infections* / prevention & control
Humans
Pre-Exposure Prophylaxis*

Substances

Anti-HIV Agents

Grants and funding

P30 AI060354/AI/NIAID NIH HHS/United States